Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Moreau, P., San Miguel, J., Sonneveld, P., Mateos, M.V., Zamagni, E., Avet-Loiseau, H., Hajek, R., Dimopoulos, M.A., Ludwig, H., Einsele, H., Zweegman, S., Facon, T., Cavo, M., Terpos, E., Goldschmidt, H., Attal, M., Buske, C.

Volltext

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Dimopoulos, M.A., Moreau, P., Terpos, E., Mateos, M.V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., Goldschmidt, H., Facon, T., Einsele, H., Boccadoro, M., San-Miguel, J., Sonneveld, P., Mey, U.

Volltext

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma von Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z, Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O’Dwyer, Michael, Perrot, Aurore, Venner, Christopher P, Weisel, Katja, Mace, Joseph R, Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M, Kobos, Rachel, Qi, Ming, Usmani, Saad Z

Volltext

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases von Saad, F., Brown, J.E., Van Poznak, C., Ibrahim, T., Stemmer, S.M., Stopeck, A.T., Diel, I.J., Takahashi, S., Shore, N., Henry, D.H., Barrios, C.H., Facon, T., Senecal, F., Fizazi, K., Zhou, L., Daniels, A., Carrière, P., Dansey, R.

Volltext

Targeting MYC in multiple myeloma von Jovanović, K. K., Roche-Lestienne, C., Ghobrial, I. M., Facon, T., Quesnel, B., Manier, S.

Volltext

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network von Terpos, E., Sezer, O., Croucher, P.I., García-Sanz, R., Boccadoro, M., San Miguel, J., Ashcroft, J., Bladé, J., Cavo, M., Delforge, M., Dimopoulos, M.-A., Facon, T., Macro, M., Waage, A., Sonneveld, P.

Volltext

SLAMF7 and Combinational Monoclonal Antibodies Therapy von Facon, T

Volltext

Continuous Therapy for Elderly Newly Diagnosed Multiple Myeloma von Facon, T

Volltext

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR von Chng, W-J, Goldschmidt, H, Dimopoulos, M A, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, H H, Mohamed, N, Feng, S, Aggarwal, S, Hájek, R

Volltext

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM s... von Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub‐Agha, I., Schiano De Colella, J.‐M., Brisou, G., Talbot, A., Decaux, O., Houot, R., Le Gouill, S., Bigot, N., Facon, T., Corre, J., Moreau, P., Arnulf, B.

Volltext

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials von JAGANNATH, S, RICHARDSON, P. G, SONNEVELD, P, SCHUSTER, M. W, IRWIN, D, STADTMAUER, E. A, FACON, T, HAROUSSEAU, J.-L, COWAN, J. M, ANDERSON, K. C

Volltext

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study von Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hájek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, H H, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, M A

Volltext

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma von Dimopoulos, M A, Leleu, X, Palumbo, A, Moreau, P, Delforge, M, Cavo, M, Ludwig, H, Morgan, G J, Davies, F E, Sonneveld, P, Schey, S A, Zweegman, S, Hansson, M, Weisel, K, Mateos, M V, Facon, T, Miguel, J F S

Volltext

Minor clone provides a reservoir for relapse in multiple myeloma von Magrangeas, F, Avet-Loiseau, H, Gouraud, W, Lodé, L, Decaux, O, Godmer, P, Garderet, L, Voillat, L, Facon, T, Stoppa, A M, Marit, G, Hulin, C, Casassus, P, Tiab, M, Voog, E, Randriamalala, E, Anderson, K C, Moreau, P, Munshi, N C, Minvielle, S

Volltext

Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’” von Dimopoulos, M.A., Moreau, P., Terpos, E., Mateos, M.V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., Goldschmidt, H., Facon, T., Einsele, H., Boccadoro, M., San-Miguel, J., Sonneveld, P., Mey, U.

Volltext

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies von Ludwig, Heinz, Khayat, David, Giaccone, Giuseppe, Facon, Thierry

Volltext

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients von Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, Avet-Loiseau, H

Volltext

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial von Bahlis, N J, Corso, A, Mugge, L-O, Shen, Z-X, Desjardins, P, Stoppa, A-M, Decaux, O, de Revel, T, Granell, M, Marit, G, Nahi, H, Demuynck, H, Huang, S-Y, Basu, S, Guthrie, T H, Ervin-Haynes, A, Marek, J, Chen, G, Facon, T

Volltext

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy von Giles, F J, Abruzzese, E, Rosti, G, Kim, D-W, Bhatia, R, Bosly, A, Goldberg, S, Kam, G L S, Jagasia, M, Mendrek, W, Fischer, T, Facon, T, Dünzinger, U, Marin, D, Mueller, M C, Shou, Y, Gallagher, N J, Larson, R A, Mahon, F-X, Baccarani, M, Cortes, J, Kantarjian, H M

Volltext

Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: [Ann Oncol 2021; 32(3): 309-322] von Dimopoulos, M.A., Moreau, P., Terpos, E., Mateos, M.V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., Goldschmidt, H., Facon, T., Einsele, H., Boccadoro, M., San-Miguel, J., Sonneveld, P., Mey, U.

Volltext